chc 1295 ipamorelin CJC-1295 No DAC + 10mg CJC-1295 (Mod GRF 1-29) &

The subcutaneous injection allows for a slow and sustained release of the peptide into the bloodstream

It is the canonical GHRH-analogue + GHRP research pairing CJC-1295 (no DAC), a stabilised 30-residue GHRH analogue, co-lyophilised in a single vial with Ipamorelin, a selective ghrelin / growth-hormone-secretagogue-receptor (GHS-R1a) agonist

This helps to minimize the counter-regulatory action of GH against higher daytime insulin levels (and its potential for increasing insulin resistance)

Modified GRF(1-29), protease-resistant synthetic GHRH(1-29) analog (no albumin-binding DAC) The pathways CJC-1295 acts on and what each one does